Can short-term hormone therapy for rising PSA prolong survival?
Mené en France sur 743 patients atteints d'un adénocarcinome de la prostate de stade pT2, pT3 ou pT4a avec récidive biochimique après prostatectomie radicale (âge : 18 ans ou plus), cet essai multicentrique de phase III évalue le bénéfice, en termes de survie sans progression, et la toxicité de l'ajout d'un traitement anti-androgénique de courte durée à une radiothérapie de sauvetage
Despite the use of radiation therapy for the recurrence of prostate-specific antigen (PSA) after radical prostatectomy, prostate cancer can recur and cause death in some men.1 In the newly diagnosed setting, results from randomised studies have shown that addition of androgen deprivation therapy to radiation therapy prolongs survival in men with unfavourable-risk prostate cancer;2 therefore, investigating this therapeutic approach in the setting of PSA recurrence after radical prostatectomy is a clinically important question.
The Lancet Oncology , commentaire, 2015